Envista Holdings
NVST Mid CapHealthcare · Medical Instruments & Supplies
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Envista Holdings en bref
Envista Holdings (NVST) is currently trading at 22,58 € with a market capitalization of 3,7 Md €. The trailing P/E ratio stands at 63.17x, with a forward P/E of 16.48x. The 52-week range spans from 15,97 € to 26,52 €; the current price is 14.9% below the yearly high. Year-over-year revenue growth stands at +14.4%. The net profit margin stands at 2.41%.
💰 Dividende
Envista Holdings currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
13 analystes évaluent Envista Holdings (NVST) au consensus : Acheter. L'objectif de cours moyen est de 25,88 €, soit un potentiel de +14.64% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 18,31 € à 30,51 €.
Envista Holdings : la thèse d'investissement en détail
Envista Holdings (NVST) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 14.4% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 130% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.
Le scénario baissier
With a net margin of just 2.41%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
À surveiller
- The forward P/E of 16.48x is meaningfully below the trailing 63.17x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 55.25% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Free cash flow positif
- –Faible rentabilité (marge 2.41%)
- –Multiple de valorisation élevé (P/E 63.17x)
- –Actuellement jugée surévaluée
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (8.16%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Envista Holdings?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
